Synlogic Moves Synthetic Biotics To The Clinic For Rare Metabolic Disease
Executive Summary
Emerging Company Profile: Pioneering the development of a new class of living medicines that work in the microbiome, Synlogic completed a reverse merger earlier this year that took the company public.
You may also be interested in...
Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
Synlogic Pivots After First Clinical Failure
The synthetic biotics company is discontinuing development of SNYB1020, its first clinical-stage product, which failed to lower blood ammonia in cirrhosis patients.
Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs
Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.